These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Eshaghi A; Prados F; Brownlee WJ; Altmann DR; Tur C; Cardoso MJ; De Angelis F; van de Pavert SH; Cawley N; De Stefano N; Stromillo ML; Battaglini M; Ruggieri S; Gasperini C; Filippi M; Rocca MA; Rovira A; Sastre-Garriga J; Vrenken H; Leurs CE; Killestein J; Pirpamer L; Enzinger C; Ourselin S; Wheeler-Kingshott CAMG; Chard D; Thompson AJ; Alexander DC; Barkhof F; Ciccarelli O; Ann Neurol; 2018 Feb; 83(2):210-222. PubMed ID: 29331092 [TBL] [Abstract][Full Text] [Related]
7. The role of global and regional gray matter volume decrease in multiple sclerosis. Grothe M; Lotze M; Langner S; Dressel A J Neurol; 2016 Jun; 263(6):1137-45. PubMed ID: 27094570 [TBL] [Abstract][Full Text] [Related]
13. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C JAMA Neurol; 2022 Jul; 79(7):682-692. PubMed ID: 35575778 [TBL] [Abstract][Full Text] [Related]
14. Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis. Weeda MM; van Nederpelt DR; Twisk JWR; Brouwer I; Kuijer JPA; van Dam M; Hulst HE; Killestein J; Barkhof F; Vrenken H; Pouwels PJW J Neurol; 2024 Jan; 271(1):355-373. PubMed ID: 37716917 [TBL] [Abstract][Full Text] [Related]
15. Interpretable and Intuitive Machine Learning Approaches for Predicting Disability Progression in Relapsing-Remitting Multiple Sclerosis Based on Clinical and Gray Matter Atrophy Indicators. Yan Z; Shi Z; Zhu Q; Feng J; Liu Y; Li Y; Zhou F; Zhuo Z; Ding S; Wang X; Yin F; Tang Y; Lin B; Li Y Acad Radiol; 2024 Jul; 31(7):2910-2921. PubMed ID: 38429188 [TBL] [Abstract][Full Text] [Related]
16. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095 [TBL] [Abstract][Full Text] [Related]
17. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis. AbdelRazek MA; Tummala S; Khalid F; Tauhid S; Jalkh Y; Khalil S; Hurwitz S; Zurawski J; Bakshi R J Neurol Sci; 2023 Jan; 444():120501. PubMed ID: 36481574 [TBL] [Abstract][Full Text] [Related]
18. Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers. Bussas M; Grahl S; Pongratz V; Berthele A; Gasperi C; Andlauer T; Gaser C; Kirschke JS; Wiestler B; Zimmer C; Hemmer B; Mühlau M Mult Scler; 2022 May; 28(6):900-909. PubMed ID: 34591698 [TBL] [Abstract][Full Text] [Related]
19. Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis. Riccitelli GC; Pagani E; Rodegher M; Colombo B; Preziosa P; Falini A; Comi G; Filippi M; Rocca MA Mult Scler; 2019 Feb; 25(2):204-216. PubMed ID: 29173009 [TBL] [Abstract][Full Text] [Related]
20. Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates. Rekik A; Aissi M; Rekik I; Mhiri M; Frih MA Brain Behav; 2022 May; 12(5):e2573. PubMed ID: 35398999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]